03.08.25 -- Life Science Leader Best Of February

Recent court rulings have changed the way branded and generic drug manufacturers should think about patent listings in the FDA Orange Book. Hatch-Waxman experts at Polsinelli detail the changes and implications and make predictions about what comes next.

Simon-Kucher's industry study reveals barriers and success factors for improving global pricing and marketing access strategies, from core markets to the local affiliate level in non-core markets.

Strong private equity investment and strategic M&A in 2024, and a shift toward clinical-stage companies and asset-driven strategies, have set the healthcare and biotech industries on a positive trajectory for 2025.

Antibody-based therapeutics are increasing in popularity. Analyze the hurdles of antibody development and manufacturing, and explore exciting developments.

This "In Their Shoes" video shares LaToya Bolds-Johnson's journey with breast cancer and her advice to others going through similar struggles.

This insightful roundtable discussion delves into the findings from Greenphire’s 2024 Market Trends Survey. Experts uncover the key challenges and priorities shaping clinical trials in 2025.